Zymergen Expands Agreement with Octant to Scale Next-Generation Drug Discovery Platform
14 Julio 2022 - 3:56PM
Zymergen Inc. (“Zymergen” or the “Company”) today announced it has
expanded its agreement with Octant to further scale their
next-generation platform to develop breakthrough medicines. In May,
Octant purchased five Reconfigurable Automation Carts, or RACs, to
improve the throughput, efficiency, and reliability of operations
for its existing platform. Octant has now more than doubled its
initial investment through the purchase of an additional six RAC
units, vastly increasing the system’s throughput, capabilities, and
ability to run complex workflows.
“We’ve been extremely pleased with the performance of our
current RAC System and are looking forward to expanding the
system’s capabilities in Stage 2,” said Sri Kosuri, Co-founder and
Chief Executive Officer of Octant. “We’re confident that this next
stage will deliver capabilities to accelerate the growth of our
platform and advance our mission to develop life-changing medicines
for some of the world’s most challenging diseases.”
“We are thrilled with the expansion of Octant’s RAC System and
with the success of their Stage 1 System thus far,” said Will
Serber, Zymergen’s Head of Automation. “It’s been an incredible
journey to watch this technology develop internally at Zymergen and
even more rewarding to now see it outside of Zymergen, supporting
other companies’ missions.”
About Zymergen’s Automation Technology
Zymergen’s automation technology is designed to improve the
throughput, efficiency, and reliability of lab operations. It is
based on building blocks called Reconfigurable Automation Carts, or
RACs, which house task-targeted instruments like liquid handlers
and analytical devices. RACs are easily connected to form a raceway
that moves plates from station to station and can be controlled
remotely by Zymergen’s cloud software that schedules workflows,
monitors progress, and collects scientific, process, and instrument
performance data. A RAC system can scale to various sizes depending
on throughput and application, and can be reconfigured in a matter
of hours. See more at zymergen.com/automation.
About Zymergen
Zymergen is a biotech company that designs and produces
molecules, microbes and materials for diverse end markets. We
partner with nature to make better products, a better way, for a
better world. For more information visit www.zymergen.com.
About Octant
Octant is a next-generation therapeutics company integrating
novel and scaled experimental technologies (multiplexed
measurements and high-throughput synthetic chemistry) with
computation to solve complex challenges in drug discovery. Octant
engineers drugs with novel mechanisms of action guided by extensive
proprietary datasets in engineered human cells that unlock insights
between genomes, drug candidates, biochemical function, and disease
phenotypes. The Octant platform uses synthetic biology, high
throughput multiplexed assays, synthetic chemistry, and computation
to engineer and interrogate drugs, proteins, and cellular pathways
at unprecedented scales. For more information visit
www.octant.bio.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended. Such forward-looking statements are based on the
Company’s beliefs and assumptions and on information currently
available to it on the date of this press release. In some cases,
you can identify these statements by forward-looking words such as
“may,” “will,” “continue,” “anticipate,” “intend,” “could,”
“project,” “expect” or the negative or plural of these words or
similar expressions. Forward-looking statements in this press
release, include but are not limited to statements regarding the
customer pipeline for our automation business, the potential
benefits of our automation technology and services to our
customers, and our expectations for future enhancement and
expansion of our automation technology and services for our
customers. Forward-looking statements may involve known and unknown
risks, uncertainties and other factors that may cause the Company’s
actual results, performance or achievements to be materially
different from those expressed or implied by the forward-looking
statements, including, but not limited to, risks relating to the
Company’s ability to attract and retain automation customers and to
provide and expand its automation technology and services for its
customers. These and other risks are described more fully in the
Company’s filings with the Securities and Exchange Commission,
including the Company’s Quarterly Report on Form 10-Q for the
quarter ended March 31, 2022, and other documents the Company
subsequently files with the SEC. Except to the extent required by
law, the Company undertakes no obligation to update such statements
to reflect events that occur or circumstances that exist after the
date on which they were made.
Zymergen Investor
Contactinvestors@zymergen.com
Octant, Inc. Media
Contactspress@octant.bio
Zymergen (NASDAQ:ZY)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Zymergen (NASDAQ:ZY)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024